Antiparasitic drugs market seen reaching $36.13 billion by 2030

By AI, Created 10:38 AM UTC, May 20, 2026, /AGP/ – The global antiparasitic drugs market is projected to grow from $25.58 billion in 2025 to $36.13 billion by 2030, driven by rising parasitic infections, veterinary demand and new treatment approaches. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The antiparasitic drugs market is expanding as parasitic and vector-borne diseases continue to pressure human and animal health systems. - The forecast points to stronger demand for treatments across human medicine, veterinary care and livestock protection. - The market’s expected growth to $36.13 billion by 2030 signals continued investment in drug development, delivery systems and combination therapies.

What happened: - The Business Research Company said the global antiparasitic drugs market will rise from $25.58 billion in 2025 to $27.18 billion in 2026. - The market is projected to reach $36.13 billion by 2030, at a compound annual growth rate of 7.4%. - The company published the projection on May 8, 2026. - A free sample of the report is available here. - The full report is available here.

The details: - The market grew at a 6.2% CAGR in the historical period, according to the report. - Rising parasitic disease prevalence, limited access to advanced drugs in developing countries and continued use of monotherapy treatments supported earlier growth. - Growing demand in veterinary care and low awareness of prevention methods also contributed to expansion. - Future growth is expected to come from combination therapies, precision medicine, new drug delivery systems and expansion into emerging markets. - The report highlights rising parasitic infection rates, combination antiparasitic medications, broader use in animal healthcare, more oral and injectable treatments, and new antiparasitic agents as major trends. - Antiparasitic drugs treat infections caused by parasites in humans, animals and plants. - The drugs work by eliminating parasites or limiting their ability to multiply and survive in a host. - Vector-borne diseases are a major growth driver for the market. - Mosquitoes, ticks and flies transmit these diseases, including malaria, dengue and yellow fever. - Chloroquine, doxycycline and atovaquone-proguanil are among the medications commonly used for malaria treatment. - The US Centers for Disease Control and Prevention reported more than 9.7 million dengue cases across the Americas from January to June 2024, more than double the 4.6 million cases recorded in 2023. - Puerto Rico accounted for 1,498 dengue cases in the United States, and 745 cases were found among travelers returning from affected regions. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The market analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a shift from older treatment patterns toward more targeted and combination-based therapies. - The CDC dengue figures show how outbreaks can quickly lift demand for antiparasitic medicines beyond traditional endemic markets. - Veterinary and livestock applications are becoming more important to market growth, not just human treatment.

What’s next: - The report points to continued adoption of combination therapies and precision medicine. - Drug makers are likely to focus on new delivery systems and novel agents as demand broadens. - Asia-Pacific’s faster growth suggests the market’s next expansion phase may be led by emerging economies and higher disease burden regions.

The bottom line: - The antiparasitic drugs market is on track for steady expansion, with rising infection rates and broader use across human and animal health driving the next leg of growth.